Bioquell Regulatory News (BQE)

17 January, 2014

BIOQUELL PLC

Pre-close update on the year ended 31 December 2013

Bioquell PLC ("Bioquell") (LSE symbol: BQE) - provider of specialist microbiological control technologies to the international Healthcare, Life Sciences & Defence markets; and specialist testing services in the UK via its TRaC division, today announces an update on its trading performance prior to entering the closed period ahead of the preliminary results for the year to 31 December 2013.

Trading remained broadly consistent with that disclosed in the Interim Management Statement on 15 November, 2013.

We estimate that orders for the year ended 31 December, 2013 will be approximately £48.7 million (2012: £44.6 million), an increase in the year of some 9%; and revenues will be approximately £44.6 million (2012: 41.0 million), an increase in the year of some 9%.

The preliminary results for the year ended 31 December, 2013 will be announced on 18 March, 2014.

*********************

Note the information contained in the announcement above is unaudited and has been prepared from unaudited internal management accounting information.

- Ends -

Enquiries:

Bioquell PLC 01264 835 900

Nigel Keen Chairman

Nick Adams Group Chief Executive

Mark Bodeker Chief Operating Officer / Finance Director

*******************

Notes to editors:

§ The Group is a UK-headquartered, international technology company with two divisions:

o Bioquell (www.bioquell.com) which sells specialist bio-contamination control products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and

o TRaC (www.tracglobal.com) which provides specialist Testing, Regulatory and Compliance services - including EMC, environmental and safety testing - principally to UK corporates.

§ Bioquell's bio-contamination control technology is principally based around hydrogen peroxide vapour ("HPV") - which is highly efficacious at eradicating micro-organisms such as bacteria and viruses at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen (hence an extremely 'green' technology) at the end of the bio-decontamination process.

§ For the last three years Bioquell has invested substantial sums in developing a new product range which has been designed to increase the proportion of recurring revenues from its HPV technology - and hence increase its quality of earnings.

§ Bioquell's bio-contamination control technology:

o is used by bio-pharmaceutical, biotechnology and research institutions to provide sterile equipment and/or sterile working environments;

o is used to eradicate "superbugs" from hospitals; independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces significantly the rates of hospital acquired infection;

o is used to provide single rooms to hospitals (via the ICE-pod) which currently only have open, multi-bed "Nightingale" ward structures

o has been incorporated in a wound-care product - BioxyQuell - which has received regulatory approval for use on chronic wounds in the European Union; and

§ Bioquell currently has overseas operations in the USA, France, Ireland, Singapore, China and Brazil.

TRaC sells its specialist services to the product development departments of a broad range of companies, principally based in the UK, with a particular focus on organisations operating in the aerospace and defence sectors.